Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02318303 · ClinicalTrials.gov registry record · Phase 2
To Study GSP 301 in Patients With Seasonal Allergic Rhinitis
A Phase 2 study, sponsored by Glenmark Pharmaceuticals Ltd. India.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,111
- Enrollment target
NCT02318303 is a Phase 2 study that has completed, run by Glenmark Pharmaceuticals Ltd. India. The registered enrollment target is 1,111 participants.
The verdict
NCT02318303, a Phase 2 study, has completed, sponsored by Glenmark Pharmaceuticals Ltd. India.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,111 participants
- Enrollment target
Study Summary
Study to evaluate the two different strengths and dose regimen of GSP 301 to be effective in treatment of seasonal allergic rhinitis.
Interventions
- DRUG GSP 301 Placebo NS
- DRUG GSP 301-1 NS (QD)
- DRUG GSP 301-2 NS (BID)
- DRUG Olopatadine HCl-1 NS (QD)
- DRUG Olopatadine HCl-2 NS (BID)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,111 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02318303
The ClinicalTrials.gov registry entry for NCT02318303 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glenmark Pharmaceuticals Ltd. India, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which GSP 301 Placebo NS is the first listed.
NCT02318303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02318303 about?
NCT02318303 is a clinical study titled "To Study GSP 301 in Patients With Seasonal Allergic Rhinitis". Study to evaluate the two different strengths and dose regimen of GSP 301 to be effective in treatment of seasonal allergic rhinitis.
What is the current status of trial NCT02318303?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,111 participants. The study started on 2014-12. Estimated completion is 2015-02.
What interventions are being tested in trial NCT02318303?
The interventions under investigation include: GSP 301 Placebo NS (DRUG), GSP 301-1 NS (QD) (DRUG), GSP 301-2 NS (BID) (DRUG), Olopatadine HCl-1 NS (QD) (DRUG), Olopatadine HCl-2 NS (BID) (DRUG).
Who is sponsoring clinical trial NCT02318303?
This trial is sponsored by Glenmark Pharmaceuticals Ltd. India, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.